Quantum Materials represent a frontier research endeavour. The strong interactions at the heart of their exotic physical properties has made understanding, let alone predicting, their materials properties one of the most profound challenges of modern-day solid state physics and materials chemistry. This problem is not just an intellectual curiosity, however; harnessing control over the collective states that these systems can host, such as superconductivity, metal-insulator transitions, and magnetic orderings, could open new routes to designing fast, energy-efficient, and smart multifunctional technologies, operating using completely different design principles to the Silicon-based logic of today. To progress towards an improved fundamental understanding, and thereby ultimate exploitation, of these systems requires controlled, new, experimental approaches. Here, we propose to develop new capabilities for applying large, reversible, and continuously-tuneable uniaxial pressures in conjunction with angle-resolved photoemission experiments. This promises novel insight into how the electronic structures and many-body interactions of quantum materials evolve when subjected to a particularly clean tuning parameter, which is of fundamental importance to further our understanding of the quantum many-body problem in solids. To this end, we will focus on two key materials systems, the metallic transition-metal dichalcogenides and the layered ruthenate oxides. These are each of enormous current interest in their own right, as potential hosts of topological excitations, as new 2D materials candidates, and as unconventional magnets, and are chosen here to provide important complementary insights into the nature of phase competition, electron-lattice interactions, and strong electronic correlations in solids.

Molecular sciences, such as chemistry, biophysics, molecular biology and protein science, are vital to innovations in medicine and the discovery of new medicines and diagnostics. As well as making a crucial contribution to health and society, industries in this field provide an essential component to the economy and contribute hugely to employment figures, currently generating nearly 500,000 jobs nationally. To enable and facilitate future economic growth in this area, the CDT will provide a cohort of researchers who have training in both aspects of this interface who will be equipped to become the future innovators and leaders in their field. All projects will be based in both molecular and medical sciences and will focus on unmet medical needs, such as understanding of disease biology, identification of new therapeutic targets, and new approaches to discovery and development of novel therapies. Specific problems will be identified by researchers within the CDT, industrial partners, stakeholders and the CDT students. The research will be structured around three theme areas: Biology of Disease, Molecule and Assay Design and Structural Biology and Computation. The CDT brings together leading researchers with a proven track record across these areas and who have pioneered recent advances in the field, such as multiple approved cancer treatments. Their combined expertise will provide supervision and mentorship to the student cohort who will work on projects that span these research themes and bring their contributions to bear on the medical problems in question. The student cohort approach will allow teams of researchers to work together on joint projects with common goals. Projects will be proposed between academics, industrial partners and students with priority given to those with industrial relevance. The programme of research and training across the disciplines will equip graduates of the CDT with an unprecedented background of knowledge and skills across the disciplines. The programme of research and training across the disciplines will be supplemented by training and hands-on experiences of entrepreneurship, responsible innovation and project management. Taken together this will make graduates of the CDT highly desirable to employers, equip them with the skills they need to envisage and implement future innovations in the area and allow them to become the leaders of tomorrow. A structured and highly experienced management group, consisting of a director, co-directors, theme leads and training coordinators will oversee the execution of the CDT with the full involvement of industry partners and students. This will ensure delivery of the cohort training programme and joint events as well as being accountable for the process of selection of projects and student recruitment. The management team has an established track record of delivery of research and training in the field across industry and academia as well as scientific leadership and network training coordination. The CDT will be delivered as a single, fully integrated programme between Newcastle and Durham Universities, bringing together highly complementary skills and backgrounds from the two institutions. The seamless delivery of the programme across the two institutions is enabled by their unique connectivity with efficient transport links and established regional networks. The concept and structure of the CDT has been developed in conjunction with the industrial partners across the pharmaceutical, biotech and contract research industries, who have given vital steer on the desirability and training need for a CDT in this area as well as to the nature of the theme areas and focus of research. EPSRC funding for the CDT will be supplemented by substantial contributions from both Universities with resources and studentship funding and from industry partners who will provide training, in kind contribution and placements as well as additional studentships.